基于微流控多细胞芯片模型的卵巢癌CAR-T 疗法疗效及病理评价研究
CSTR:
作者:
作者单位:

郑州大学第五附属医院

作者简介:

通讯作者:

中图分类号:

基金项目:


Study on the efficacy and pathological evaluation of CAR-T therapy for ovarian cancer based on microfluidic multi-cellular chip model
Author:
Affiliation:

The Fifth Affiliated Hospital of Zhengzhou University

Fund Project:

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
  • |
  • 文章评论
    摘要:

    目的 构建一种仿生微流控卵巢癌多细胞芯片模型,用于在体外模拟肿瘤微环境,并系统评价嵌合抗原受体T细胞(chimeric antigen receptor T cells,CAR-T)疗法的疗效及相关病理学改变。方法 前瞻性收集106例上皮性卵巢癌(epithelial ovarian cancer,EOC)患者标本。将其与癌相关成纤维细胞(cancer-associated fibroblasts,CAFs)、人脐静脉内皮细胞(human umbilical vein endothelial cells,HUVECs)整合,在微流控芯片中构建三维多细胞肿瘤球模型。将靶向间皮素(mesothelin,MSLN)的CAR-T细胞注入芯片进行动态灌注共培养。根据干预方式不同分为MSLN-CAR-T组(n=10)和普通T细胞组(n=10)。培养7 d后,收集芯片内多细胞球聚体,病理染色观察观察模型病理结构,并评估模型靶抗原表达异质性。采用细胞活-死染色检测肿瘤细胞存活率;免疫荧光双标染色检测CAR-T细胞浸润能力。采用免疫荧光双标染色检测内皮细胞激活状态;酶联免疫吸附试验(enzyme-linked immunosorbent assay,ELISA)分别检测灌流液中白介素(interleukin,IL)-6、肿瘤坏死因子-α(tumor necrosis factor-α,TNF-α)及干扰素-γ(interferon-γ,IFN-γ)浓度。结果 成功构建了涵盖多种病理亚型的卵巢癌芯片模型。共培养72 h后,MSLN-CAR-T组肿瘤细胞存活率显著低于普通T细胞组(P<0.001);CAR-T细胞浸润深度显著大于普通T细胞组(P<0.001)。IL-6、TNF-α和IFN-γ的浓度随时间变化均呈递增趋势(均P<0.05)。MSLN-CAR-T组血管周围的细胞间黏附分子-1(intercellular adhesion molecule-1,ICAM-11)表达强度随距离肿瘤球的减小而显著增加(P<0.05)。结论 本研究建立的芯片模型能够有效模拟体内肿瘤微环境,为CAR-T疗法的临床前评价提供了一个高通量、可重复的精准平台。

    Abstract:

    Objective To construct a bionic microfluidic multicellular chip model of ovarian cancer, which can be used to simulate the tumor microenvironment in vitro and systematically evaluate the efficacy and related pathological changes of chimeric antigen receptor T cell (CAR-T) therapy. Methods A total of 106 patients with epithelial ovarian cancer (EOC) were prospectively collected from surgical specimens, which were integrated with cancer-associated fibroblasts (CAFs) and human umbilical vein endothelial cells (HUVECs) to construct a three-dimensional multicellular tumor sphere model in microfluidic microarray. Moreover, CAR-T cells targeting mesothelin (MSLN) were injected into the microfluidic chip for dynamic perfusion co-culture. According to the different intervention methods, they were divided into: the MSLN-CAR-T group (n=10) and the ordinary T cell group (n=10). After 7 days of cultivation, the multicellular spheroids within the chip were collected. Pathological staining was employed to observe the pathological structure of the model, and the heterogeneity of target antigen expression in the model was evaluated. The survival rate of tumor cells was detected using cell viability/death staining. Immunofluorescence double-labeling staining was used to detect the infiltration ability of CART cells. The activation status of endothelial cells was detected by immunofluorescence double-labeling staining. The enzyme-linked immunosorbent assay (ELISA) was used to separately detect the concentrations of interleukin (IL)-6, tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) in the perfusate. Results A microarray model of ovarian cancer covering multiple pathological subtypes was successfully constructed. After 72 hours of co-culture, the survival rate of tumor cells in MSLN-CAR-T group was significantly lower than that in the ordinary T cell group (P<0.001), and the infiltration depth of CAR-T cells was significantly greater than that in the ordinary T cell group (P<0.001). The concentrations of IL-6, TNF- α and IFN- γ all showed an increasing trend over time (all P<0.05). The expression intensity of intercellular adhesion molecule-1 (ICAM-1) around the blood vessels in the MSLN-CAR-T group significantly increased as the distance from the tumor sphere decreased (P<0.05). Conclusion The chip model established in this study can effectively simulate the tumor microenvironment in vivo, thus providing a high-throughput, reproducible and accurate platform for preclinical evaluation of CAR-T therapy.

    参考文献
    相似文献
    引证文献
引用本文

张星.基于微流控多细胞芯片模型的卵巢癌CAR-T 疗法疗效及病理评价研究[J].生物医学工程学进展,2026,(4):204-209

复制
分享
相关视频

文章指标
  • 点击次数:
  • 下载次数:
  • HTML阅读次数:
  • 引用次数:
历史
  • 收稿日期:2026-07-03
  • 最后修改日期:2026-07-14
  • 录用日期:2026-07-16
  • 在线发布日期: 2026-10-20
  • 出版日期:
文章二维码